| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:MC-1-F2
CAS:2376894-10-7
Purity:97.92% Package:25mg/RMB 10600;50mg/RMB 13800;100mg/RMB 17500
|
Guanidine, N-[4-[[4-[4-[4-amino-6-[[4-(4-morpholinyl)phenyl]amino]-1,3,5-triazin-2-yl]-1-piperazinyl]-6-[(4-phenoxyphenyl)amino]-1,3,5-triazin-2-yl]amino]butyl]- manufacturers
- MC-1-F2
-
- $1480.00 / 25mg
-
2025-11-09
- CAS:2376894-10-7
- Min. Order:
- Purity: 98.44%
- Supply Ability: 10g
|
| | Guanidine, N-[4-[[4-[4-[4-amino-6-[[4-(4-morpholinyl)phenyl]amino]-1,3,5-triazin-2-yl]-1-piperazinyl]-6-[(4-phenoxyphenyl)amino]-1,3,5-triazin-2-yl]amino]butyl]- Basic information |
| Product Name: | Guanidine, N-[4-[[4-[4-[4-amino-6-[[4-(4-morpholinyl)phenyl]amino]-1,3,5-triazin-2-yl]-1-piperazinyl]-6-[(4-phenoxyphenyl)amino]-1,3,5-triazin-2-yl]amino]butyl]- | | Synonyms: | MC-1-F2;Guanidine, N-[4-[[4-[4-[4-amino-6-[[4-(4-morpholinyl)phenyl]amino]-1,3,5-triazin-2-yl]-1-piperazinyl]-6-[(4-phenoxyphenyl)amino]-1,3,5-triazin-2-yl]amino]butyl]- | | CAS: | 2376894-10-7 | | MF: | C37H46N16O2 | | MW: | 746.87 | | EINECS: | | | Product Categories: | | | Mol File: | 2376894-10-7.mol | ![Guanidine, N-[4-[[4-[4-[4-amino-6-[[4-(4-morpholinyl)phenyl]amino]-1,3,5-triazin-2-yl]-1-piperazinyl]-6-[(4-phenoxyphenyl)amino]-1,3,5-triazin-2-yl]amino]butyl]- Structure](CAS/20240320/GIF/2376894-10-7.gif) |
| | Guanidine, N-[4-[[4-[4-[4-amino-6-[[4-(4-morpholinyl)phenyl]amino]-1,3,5-triazin-2-yl]-1-piperazinyl]-6-[(4-phenoxyphenyl)amino]-1,3,5-triazin-2-yl]amino]butyl]- Chemical Properties |
| Boiling point | 996.4±75.0 °C(Predicted) | | density | 1.46±0.1 g/cm3(Predicted) | | pka | 13.79±0.70(Predicted) | | form | Solid | | color | White to off-white |
| | Guanidine, N-[4-[[4-[4-[4-amino-6-[[4-(4-morpholinyl)phenyl]amino]-1,3,5-triazin-2-yl]-1-piperazinyl]-6-[(4-phenoxyphenyl)amino]-1,3,5-triazin-2-yl]amino]butyl]- Usage And Synthesis |
| Description | MC-1-F2 is the first inhibitor of forkhead Box Protein C2 (FOXC2). | | Uses | MC-1-F2 is a FOXC2 inhibitor that reduces epithelial-mesenchymal transition (EMT) markers in breast cancer cells, suppresses cancer stem cell (CSC) properties and reduces invasiveness in castration-resistant prostate cancer (CRPC) cells. There is a synergistic effect between MC-1-F2 and Docetaxel, which has the potential to be used in combination to study CRPC[1]. | | References | [1] Castaneda M, et al. A FOXC2 inhibitor, MC-1-F2, as a therapeutic candidate for targeting EMT in castration-resistant prostate cancer. Bioorg Med Chem Lett. 2023 Jul 15;91:129369. DOI:10.1016/j.bmcl.2023.129369 |
| | Guanidine, N-[4-[[4-[4-[4-amino-6-[[4-(4-morpholinyl)phenyl]amino]-1,3,5-triazin-2-yl]-1-piperazinyl]-6-[(4-phenoxyphenyl)amino]-1,3,5-triazin-2-yl]amino]butyl]- Preparation Products And Raw materials |
|